The Role of Mitochondrial Aldehyde Dehydrogenase 2 (ALDH2) in Neuropathology and Neurodegeneration.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic concepts and preclinical data
What was done
This narrative review summarizes literature regarding the sources and consequences of reactive aldehyde toxicity ('aldehydic load' from metabolism, environmental pollutants, and lipid peroxidation) in the brain. It evaluates the neuroprotective function of mitochondrial aldehyde dehydrogenase 2 (ALDH2), the impact of the common East Asian ALDH2 deficiency variant, and the therapeutic potential of small-molecule ALDH activators (such as Alda-1) in ischemic stroke, Alzheimer's disease, and Parkinson's disease.
What was found
The abstract reports no numerical findings or statistical measures. It qualitatively describes that reactive aldehydes (including 4-HNE, DOPAL, malondialdehyde, acrolein, and acetaldehyde) form toxic adducts with cellular macromolecules, that ALDH2 deficiency is linked to neurodegenerative pathologies, and that small-molecule ALDH activators reduce neuronal death in disease models.
Why it matters
It highlights aldehydic load as a shared pathological mechanism across multiple neurological conditions and proposes ALDH2 enhancement as a targeted neuroprotective strategy.
Limits
The abstract describes a non-systematic review without defined search methods or quantitative synthesis. Data supporting ALDH2 activators derive from preclinical disease models, and clinical trial outcomes in humans are not reported.
Cited by
- partial Alcohol converts to acetaldehyde in the liver, which damages neurons and contributes to neurodegenerative diseases like dementia and Alzheimer's.